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Knowledge about association between sleep apnea and cardiovascular autonomic neuropa-
thy (CAN) in type 1 diabetes mellitus (T1DM) might give some insight into the pathogenesis
of this condition in these patients. In obese patients, excessive central adiposity, including a
large neck circumference, can contribute to obstructive sleep apnea (OSA). Its presence in
non-obese patients, however, indicates that it could be correlated with autonomic neuropa-
thy. The aim of this study was to compare the prevalence of OSA in young and lean T1DM
patients with and without CAN. We studied 20 adult, non-obese,T1DM patients who were
divided into two groups according to the results of the cardiovascular autonomic reflex
tests (CARTs). These two groups (9 with CAN and 11 without CAN) were compared to a
control group of 22 healthy individuals, who were matched by age and BMI. A polysomnog-
raphy was performed and sleep was analyzed. The CAN+ group had a significantly higher
prevalence of sleep apnea compared to the other groups (67% CAN+; 23% CAN−; 4.5%
controls: CAN+ vs. Control; p=0.006 and CAN+ vs. CAN−; p=0.02). The CAN− group
had higher sleep efficiency compared to the CAN+ group, demonstrating impaired sleep
architecture in diabetics with this chronic complication. In conclusion, OSA may be related
to the presence of CAN in young and leanT1DM patients. It could contribute to worse the
prognosis and reducing the quality of life of these patients without specific treatment of
these conditions.
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INTRODUCTION
Obstructive sleep apnea (OSA) in diabetic patients has been
frequently explained by obesity associated with type 2 diabetes
(T2DM) (1). However, little is known about the presence of OSA
in young, non-obese individuals with type-1 diabetes (T1DM).
During sleep, respiratory function is partially controlled by the
autonomic nervous system (ANS). When this system is impaired,
as in diabetic autonomic neuropathy, the airway may be less func-
tional and breathing control more variable, resulting in OSA (2, 3).
Hence, dysautonomy may favor the occurrence of OSA in diabetic
patients regardless of age and weight.
Exploring the relationship between sleep apnea and autonomic
dysfunction is an important topic of interest because it impacts
both patient care and quality of life (4). Therefore, the knowledge
of the prevalence of OSA in T1DM and its relationship with CAN
could have a high clinical benefit.
The aim of this study was to compare the prevalence of OSA in
young, lean T1DM, with and without CAN.
RESEARCH DESIGN AND METHODS
We recruited 20 adult T1DM patients with a >5-year diagnosis
with intensive insulin therapy from the Diabetes Center of the
Federal University of São Paulo. The control group (C group)
consisted of 22 healthy individuals, medical students from the
Federal University of Sao Paulo; all were young and none were
obese (BMI <25 kg/m2). The subjects were enrolled after they
signed informed consent forms. The protocol was approved by the
local ethical committee and was in accordance with the Helsinki
Declaration. All enrolled individuals completed the study.
The most recent clinical and laboratory data were taken
from the patients’ Diabetes Center file. Patients with clinical
nephropathy or non-treated thyroid disease were excluded from
the analysis.
Autonomic neuropathy was assessed by the following stan-
dard protocol of cardiovascular autonomic reflex tests (CARTs)
(5) with continuous monitoring of electrocardiography: (1) heart
rate variations with deep breathing; (2) heart rate response to the
Valsalva maneuver; (3) heart rate changes when standing from the
lying position; and (4) postural fall in systolic BP (6). A physician
specialized in diabetic neuropathy performed the exam in these
controls individuals and diabetic patients at the Diabetes Center
early in the morning. The controls and the patients have fasted for
the 8 h prior to testing and were not hypoglycemic. The presence
of CAN was defined by at least two positive tests (out of four).
Additionally, all subjects were sent to the sleep lab (UNIFESP
Sleep Institute) at 8 p.m. to perform the polysomnography exam.
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Table 1 | Clinical, metabolic characteristics, and polysomnography parameters in controls andT1DM patients with (CAN+) and without (CAN−)
cardiovascular autonomic neuropathy.
Control group T1DM CAN (–) T1DM CAN (+) p
Age (years) 23.2±3.9 27.0±8.2 32.7±6.8 NS
BMI (kg/m2) 21.8±2.14 22.1±1.8 24.5±2.5 NS
HbA1c (%) N/A 7.5±1.7 9±2.3 NS
Time from diabetes diagnosis (years) N/A 16.7±7.8 14.8±5.3 NS
ESS >9 (% of patients) 18.8 45.4 55.5 Control vs.T1DM, 0.002; CAN(−)
vs. CAN(+), 0.03
Total sleep time (min) 415.9±38.8 379.0±50.8 359.1±51.1 NS
Sleep Efficiency (%) 85.0±9.4 88.4±5.5 80.2±10.7 Control vs.T1DM, 0.002; CAN(−)
vs. CAN(+), 0.04
Microarousals (events/h) 7.0±5.0 7.7±4.1 12.4±5.1 Control vs.T1DM, 0.0003; CAN(−)
vs. CAN(+), 0.03
REM (%) 15.9±5.4 17.3±2.8 17.5±8.0 NS
SWSa (%) 20.3±7.2 22.6±6.8 18.9±9.6 NS
OSAHIb (events/h) 2.0±2.3 3.2±1.9 6.4±4.6 Control vs.T1DM, NS; CAN(−) vs.
CAN(+), 0.04
OSAHIb (% of patients) 4.5 23.0 66.6 Control vs.T1DM, 0.006; CAN(−)
vs. CAN(+), 0.01
Desaturation (%) 4.2±0.9 2.9±2.3 4.3±2.5 NS
Values are expressed as the mean and standard deviation (SD). Bold font indicates statistically significant results.
REM, rapid-eye movement.
aSWS, slow wave sleep (stages 3 and 4).
bOSAHI, obstructive sleep apnea/hypopnea index.
N/A, not available; NS, non-significant.
There, they were first tested with the Epworth Somnolence Score
(ESS), a score that subjectively measures the excessive daytime
sleepiness by asking questions about the probability of sleeping
in some situations, i.e., watching TV, driving, or waiting at the
doctor’s office. The ESS was considered positive for scores as high
as nine points (7).
Afterwards, the polysomnography (ALICE – Phillips) was per-
formed according to the recommendations of the American Sleep
Disorders Association (7). The exam was performed at night, from
10 p.m. to 6 a.m., and the patients had to avoid caffeine and
alcohol 48 h before the exam. The medication was maintained
as usual, except for psychotropic drugs, which were withdrawn
1 week before the exam. Sleep data were analyzed with con-
sideration for the sleep latency, duration, stages and efficiency,
periodic movements of the limbs, snoring, microarousals, obstruc-
tive apnea/hypopnea index (OSAHI), and saturation. Continuous
electrocardiogram and electroencephalogram were used to mon-
itor the subjects, and cameras with infrared light were used to
monitor the patient.
Obstructive sleep apnea was defined by an OSAHI that was
higher than 5/h in the polysomnography. We defined hypopnea
as an airflow reduction of 30–50% and apnea as >50%. The
microarousal index was considered positive when there were more
than 14 events/h (7). The statistical analysis was performed by
Pearson chi-square for categorical variables and t -tests for con-
tinuous variables. A univariate regression test was performed to
confirm the homogeneity of the groups. A p-value <0.05 was
considered significant (Statistic 7.0 Stat Soft Inc.; Tulsa, OK, USA).
RESULTS
We evaluated 22 non-obese young adults without diabetes
(Control group=C) and 20 patients with type 1 diabetes
(T1DM) who were also young and non-obese. We divided the
T1DM patients into two groups, positive [n= 9 (CAN+)] and
negative [n= 11; (CAN−)], according to the CAN protocol
results (6, 8, 9).
Comparing the diabetic group with the control group, the
prevalence of excessive daytime somnolence, measured by the EES,
and sleep apnea was significantly higher in the diabetic group
(p= 0.006 and p= 0.002, respectively).
The comparisons of clinical,glycemic control, and polysomnog-
raphy variables between controls, CAN (+) and CAN (−) T1DM
patients are shown in Table 1.
According to a univariate regression test, there was no difference
in the age of the studied groups.
The mean HbA1c level and the treatment schedule of these
patients were similar to the general population of T1DM patients
in São Paulo Federal University Diabetes Center.
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DISCUSSION
This is the first study reporting that young, lean, and long-
duration T1DM patients have more OSA than healthy age- and
BMI-matched individuals.
Additionally, in lean and young T1DM patients, those with
CAN have a higher prevalence of OSA, excessive daytime somno-
lence, and worse sleep architecture.
Because OSA is an uncommon finding in young and lean indi-
viduals, this high prevalence in type 1 diabetes patients, with
this profile, suggests that CAN may play an important role in its
physiopathology.
Cardiovascular autonomic neuropathy may be concomitant
with the damage of vagal reflexes, affecting the upper airway
integrity and leading, at last, to sleep apnea (10).
During normal sleep, in contrast to during wakefulness, the
parasympathetic ANS controls slow wave sleep (non-REM),
reducing sympathetic nerve traffic, heart rate, and blood pres-
sure (10). On the other hand, the sympathetic ANS is responsible
for the rapid-eye movement (REM) phase, resulting in intermit-
tent and brief surges in the blood pressure and heart rate. These
organized responses to normal sleep are completely disrupted in
patients with OSA (2, 3, 10). OSA and hypopneas commonly
result in arousals, hypoxemia, and hypercapnia, which are asso-
ciated with an increase in sympathetic activity and a decrease in
the parasympathetic activity, leading not only to higher cardiovas-
cular risk but also to higher oxidative stress and potentially CAN
impairment (10–18).
Additionally, because OSA can aggravate and amplify oxidative
stress and, ultimately, CAN, the former could contribute to the lat-
ter, resulting in a vicious circle. It is important to keep in mind that
prospective studies with a larger group of type 1 diabetic patients
are needed to determine the mutual relationship between OSA and
CAN. However, we can at least speculate that the positive impact
of CPAP treatment on oxidative stress and CAN could have sig-
nificant implications in the prognosis and quality of life of these
patients.
Furthermore, we can hypothesize that because diabetes and
OSA are associated with increased cardiovascular morbidity and
mortality, the presence of both conditions results in additive or
even synergistic health risks (19, 20).
To evaluate the prevalence of sleep apnea, we performed a
polysomnography, the gold standard test for diagnosis (7). We
know that the first night effect might impact our results. However,
all patients followed the same protocol and so the results could be
comparable.
Recently, studies have shown that the OSA per se may impact
the levels of HbA1c and the quality of life (4, 21, 22). This fact
makes the early diagnosis and treatment of this sleep distur-
bance even more important for avoiding further chronic diabetes
complications in these patients.
However, long-term follow-up studies, as we discussed previ-
ously, are needed to determine whether OSA increases the predic-
tive power of autonomic neuropathy for cardiovascular mortal-
ity. Spectral analysis during the sleep could help us determine
whether these patients are more likely to have sympathetic or
parasympathetic damage during sleep.
In conclusion, OSA may be related to the presence of CAN in
young and lean T1DM patients.
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